Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$187.39 USD

187.39
518,414

+1.13 (0.61%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $187.54 +0.15 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 245)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT

by Zacks Equity Research

Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.

Zacks Equity Research

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

by Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

Zacks Equity Research

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Zacks Equity Research

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

by Zacks Equity Research

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

Zacks Equity Research

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

by Zacks Equity Research

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Zacks Equity Research

Why Universal Health Services (UHS) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Universal Health Services (UHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Zacks Equity Research

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

by Zacks Equity Research

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Zacks Equity Research

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Zacks Equity Research

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Zacks Equity Research

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Zacks Equity Research

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Zacks Equity Research

Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Zacks Equity Research

Charles River (CRL) Launches Animal-Free Endotoxin Test

by Zacks Equity Research

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

Zacks Equity Research

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

by Zacks Equity Research

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Zacks Equity Research

Here's Why Universal Health Services (UHS) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

by Zacks Equity Research

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Zacks Equity Research

Bruker (BRKR) to Advance in Lab Automation With New Buyout

by Zacks Equity Research

This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."

Zacks Equity Research

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

by Zacks Equity Research

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

Zacks Equity Research

BD (BDX) Collaborates With Hamilton to Benefit Researchers

by Zacks Equity Research

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Zacks Equity Research

Why Universal Health Services (UHS) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.